Zhong Yuan Bio-technology Holdings Ltd

Market Cap $88.29M
Debt $3.45M
Cash $145.26K
EV $91.59M
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$271.87K
EBIT	$271.28K
ROA	9%
Equity	-$204.55K
Growth Stability	-2K%
PE	324.74
PB	-431.62
P/S	38.75
Price/Cash	0
Debt/Equity	-16.86
Net Margins	12%
Gross Margins	91%
Op. Margins	12%
Sales Growth YoY	30K%
Sales Growth QoQ	-192%
Sales CAGR	15%
Equity CAGR	4%
Earnings Growth YoY	-796%
Earnings Growth QoQ	-320%

Sales CAGR 5Y	15%
Equity CAGR 5Y	4%
Earnings CAGR 3Y	15%
Sales CAGR 3Y	15%
Equity CAGR 3Y	4%
Market Cap	$88.29M
Revenue	$2.28M
Assets	$3.17M
Total Debt	$3.45M
Cash	$145.26K
Shares Outstanding	17.69M
EV	91.59M
Working Capital	-456.51K
Current Ratio	0.82
Gross Profit	$2.07M
Shares Growth 3y	7%
Equity Growth QoQ	-38%
Equity Growth YoY	-114%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Zhong Yuan Bio-Technology Holdings Ltd is engaged in the business of developing and marketing nervonic acid-based health supplements and sales of acer truncatum seedlings. The company generates its revenue primarily from the sales of health care supplements.

SEC Filings

Direct access to Zhong Yuan Bio-technology Holdings Ltd (ZHYBF) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2018
- 10-Q Jun 30
- 10-Q Mar 31
2017
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2016
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30

Sector Comparison

How does Zhong Yuan Bio-technology Holdings Ltd compare to its competitors?

Not enough data to generate a comparison chart between Zhong Yuan Bio-technology Holdings Ltd and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Zhong Yuan Bio-technology Holdings Ltd compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Zhong Yuan Bio-technology Holdings Ltd Discounted Cash Flow

Fully customizable DCF calculator online for Zhong Yuan Bio-technology Holdings Ltd.

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	03/2019	03/2020	03/2021	03/2022	03/2023	03/2024	TTM
Net Margins	23%	-7%	-2%	-48%	-137%	12%	12%
ROA	-	-	1%	39%	-55%	9%	9%
ROE	-	-	-2%	-58%	693%	-133%	-

Good Net Margins (11.93%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	03/2019	03/2020	03/2021	03/2022	03/2023	03/2024	TTM
Debt over FCF	-	-	-	-	-1.37	-	-
Debt over Equity	0.14	0.31	0.27	0.24	-4.12	-16.86	-16.86
Growth Stability	-	-	-	-2K%	-	-	-2K%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (-16.86)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-2K%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	03/2019	03/2020	03/2021	03/2022	03/2023	03/2024	CAGR 5Y
Revenue YoY growth	-	0%	33%	43%	-29%	37%	15%
Earnings YoY growth	-	-131%	-68%	4K%	103%	-112%	-
Equity YoY growth	-	2%	1%	29%	-117%	-38%	4%
FCF YoY growth	-	-120%	-297%	-231%	150%	-	-